Hujun J. Li
Key Laboratory Of Bone Marrow Stem Cells
Xuzhou, China
Xuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.
Journal: British journal of haematology
Published: March 11, 2026
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.
Journal: Blood
Published: February 03, 2026
Efficacy and safety of chimeric antigen receptor T-cell therapy for plasma cell leukemia.
Journal: Haematologica
Published: January 03, 2026
Effect of cytoreductive chemotherapy on the incidence of differentiation syndrome in patients with newly diagnosed acute promyelocytic leukemia.
Journal: Chinese medical journal
Published: July 26, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.
Journal: The Lancet. Haematology
Published: November 30, 2024
Effect of metachronous primary and secondary solid cancers in patients with multiple myeloma: a retrospective study from a single-center.
Journal: Frontiers in immunology
Published: October 24, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma.
Journal: Clinical and experimental medicine
Published: July 07, 2024
Impact of autologous hematopoietic stem cell transplantation on the efficacy of CAR-T treatment of relapsed/refractory multiple myeloma
Journal: Zhonghua nei ke za zhi
Published: June 03, 2024
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy.
Journal: American journal of hematology
Published: May 16, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.
Journal: The Lancet. Haematology
Published: March 10, 2024
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 07, 2023
Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma.
Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: August 30, 2022
Last Updated: 09/26/2026